Entest Biomedical, Inc. Announces the Addition of Well Respected Veterinarian to Its Scientific Advisory Board (SAB) in Anticipa

Entest Biomedical, Inc. Announces the Addition of Well Respected Veterinarian to Its Scientific Advisory Board (SAB) in Anticipation of Near Term ImenVax(TM) Safety Study for Dogs


SAN DIEGO, CA--(Marketwire - November 15, 2010) - Entest BioMedical Inc. (OTCBB: ENTB) announced today it has added Dr. Gregory McDonald to its Scientific Advisory Board (SAB). The Company views this as a major step in moving forward with its immuno-therapeutic cancer vaccine for dogs, as Dr. McDonald is a practicing veterinarian and typically treats more than 700 dogs per year that have various forms of cancer.

Dr. McDonald joins Entest's SAB with a strong background in both clinical and research aspects of cancer therapy. He has authored numerous publications on many aspects of veterinary medicine. He received his Doctor of Veterinary Medicine degree (DVM) from Ohio State University in 1979. Additionally, Dr. McDonald has been involved with veterinary applications of stem cell therapies, focusing on leading edge treatments for his patients.

Entest BioMedical's Chairman & CEO David Koos stated, "I'm extremely pleased to have Dr. McDonald join our SAB. He is constantly looking to participate in scientific growth in veterinary medicine. He will be a real asset to the Company, not only in our cancer research but in other veterinary therapies as well."

A spokesperson for the Company noted that with the addition of Dr. McDonald to the Scientific Advisory Board, it gains a wealth of clinical expertise. This will greatly assist Entest as it moves forward with the ImenVaxTM cancer therapeutic products that are being developed.

About Entest BioMedical Inc.:

Entest BioMedical Inc. (OTCBB: ENTB) is a developer of veterinary medicines that harness the animal's own reparative / immunological mechanisms. The company's products include an immuno-therapeutic cancer vaccine for canines (ImenVaxTM). The company's immuno-therapeutic cancer vaccine utilizes an encapsulation device as the vaccine delivery system and requires a simple implant procedure.

Disclaimer

This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks. 


Contact:

Entest BioMedical Inc.

David R. Koos
Chairman & CEO

619.702.1404 Direct
619.330.2328 Fax
[email protected]
www.EntestBio.com

 

Suggested Articles

The CTAD presentation cleared up some questions about the dataset without delivering a telling blow for either side of the debate.

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.